MedExpress In this study, the researchers tested the vaccine’s resistance to the virulent pathogen that causes the disease and were able to demonstrate 100% protection against infection in animal models. The researchers now hope that this technology can be used to combat other lethal bacteria as well.
The study was led by Tel Aviv University’s Vice President for Research and Development Prof. Dan Peer, a global pioneer in mRNA drug development and director of the Laboratory of Precision NanoMedicine at the Shmunis School of Biomedicine and Cancer Research. He worked alongside researchers from the Israel Institute for Biological Research—Dr. Uri Elia, Dr. Yinon Levy, Dr. Emmy Mamroud, and Dr. Ofer Cohen—as well as members of his own laboratory team: Dr. Edo Kon, Dr. Inbal Hazan-Halevy, and doctoral student Shani Benarroch.